466 related articles for article (PubMed ID: 32245624)
1. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.
Prelaj A; Rebuzzi SE; Pizzutilo P; Bilancia M; Montrone M; Pesola F; Longo V; Del Bene G; Lapadula V; Cassano F; Petrillo P; Bafunno D; Varesano N; Lamorgese V; Mastrandrea A; Ricci D; Catino A; Galetta D
Clin Lung Cancer; 2020 Jul; 21(4):365-377.e5. PubMed ID: 32245624
[TBL] [Abstract][Full Text] [Related]
2. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
Prelaj A; Lo Russo G; Proto C; Signorelli D; Ferrara R; Galli G; De Toma A; Randon G; Pagani F; Trevisan B; Ganzinelli M; Zilembo N; Montrone M; Longo V; Pesola F; Pizzutilo P; Del Bene G; Varesano N; Galetta D; Torri V; Garassino MC; Di Maio M; Catino A
Clin Lung Cancer; 2020 Sep; 21(5):e337-e348. PubMed ID: 32291212
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
[TBL] [Abstract][Full Text] [Related]
5. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.
Yang Y; Xu H; Yang G; Yang L; Li J; Wang Y
Asia Pac J Clin Oncol; 2020 Feb; 16(1):63-69. PubMed ID: 31721468
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
[TBL] [Abstract][Full Text] [Related]
8. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.
Suh KJ; Kim SH; Kim YJ; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
Cancer Immunol Immunother; 2018 Mar; 67(3):459-470. PubMed ID: 29204702
[TBL] [Abstract][Full Text] [Related]
9. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Tanizaki J; Haratani K; Hayashi H; Chiba Y; Nakamura Y; Yonesaka K; Kudo K; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Ito A; Nakagawa K
J Thorac Oncol; 2018 Jan; 13(1):97-105. PubMed ID: 29170120
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of various hematological variables as markers of systemic inflammation in metastatic lung cancer.
Bayir D; Seber S; Yetisyigit T
J Cancer Res Ther; 2020; 16(4):731-736. PubMed ID: 32930111
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
[TBL] [Abstract][Full Text] [Related]
12. EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.
Prelaj A; Ferrara R; Rebuzzi SE; Proto C; Signorelli D; Galli G; De Toma A; Randon G; Pagani F; Viscardi G; Brambilla M; Trevisan B; Ganzinelli M; Martinetti A; Gallucci R; Di Mauro RM; Molino G; Zilembo N; Torri V; de Braud FM; Garassino MC; Lo Russo G
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817541
[TBL] [Abstract][Full Text] [Related]
13. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
Zattarin E; Manglaviti S; Apollonio G; Beninato T; Mazzeo L; Massa G; Bottiglieri A; Galli E; De Toma A; Occhipinti M; Brambilla M; Ferrara R; Ganzinelli M; Proto C; Garassino MC; de Braud F; Lo Russo G; Prelaj A
Future Oncol; 2022 Jul; 18(23):2593-2604. PubMed ID: 35722877
[TBL] [Abstract][Full Text] [Related]
15. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study.
Takada K; Takamori S; Matsubara T; Haratake N; Akamine T; Kinoshita F; Ono Y; Wakasu S; Tanaka K; Oku Y; Oba T; Osoegawa A; Tagawa T; Takenoyama M; Shimokawa M; Oda Y; Mori M
PLoS One; 2020; 15(11):e0241580. PubMed ID: 33137158
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.
Zer A; Sung MR; Walia P; Khoja L; Maganti M; Labbe C; Shepherd FA; Bradbury PA; Feld R; Liu G; Iazzi M; Zawisza D; Nouriany N; Leighl NB
Clin Lung Cancer; 2018 Sep; 19(5):426-434.e1. PubMed ID: 29803574
[TBL] [Abstract][Full Text] [Related]
18. Translational relevance of baseline peripheral blood biomarkers to assess the efficacy of anti-programmed cell death 1 use in solid malignancies.
Varayathu H; Sarathy V; Thomas BE; Mufti SS; Sangi L; Thungappa SC; Tripathi P; Naik R
J Cancer Res Ther; 2021; 17(1):114-121. PubMed ID: 33723141
[TBL] [Abstract][Full Text] [Related]
19. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
Sekine K; Kanda S; Goto Y; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Ohe Y
Lung Cancer; 2018 Oct; 124():179-188. PubMed ID: 30268458
[TBL] [Abstract][Full Text] [Related]
20. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
